CA3133037A1 - T cell expressing an fc gamma receptor and methods of use thereof - Google Patents

T cell expressing an fc gamma receptor and methods of use thereof Download PDF

Info

Publication number
CA3133037A1
CA3133037A1 CA3133037A CA3133037A CA3133037A1 CA 3133037 A1 CA3133037 A1 CA 3133037A1 CA 3133037 A CA3133037 A CA 3133037A CA 3133037 A CA3133037 A CA 3133037A CA 3133037 A1 CA3133037 A1 CA 3133037A1
Authority
CA
Canada
Prior art keywords
cell
cells
population
polypeptide
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3133037A
Other languages
English (en)
French (fr)
Inventor
Yaron Carmi
Peleg RIDER
Diana RASOULOUNIRIANA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of CA3133037A1 publication Critical patent/CA3133037A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/57—Skin; melanoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
CA3133037A 2019-03-19 2020-03-19 T cell expressing an fc gamma receptor and methods of use thereof Pending CA3133037A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962820357P 2019-03-19 2019-03-19
US62/820,357 2019-03-19
PCT/IL2020/050327 WO2020188570A1 (en) 2019-03-19 2020-03-19 T cell expressing an fc gamma receptor and methods of use thereof

Publications (1)

Publication Number Publication Date
CA3133037A1 true CA3133037A1 (en) 2020-09-24

Family

ID=72519182

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3133037A Pending CA3133037A1 (en) 2019-03-19 2020-03-19 T cell expressing an fc gamma receptor and methods of use thereof

Country Status (8)

Country Link
US (2) US20210401893A1 (enExample)
EP (1) EP3941492A4 (enExample)
JP (1) JP2022525927A (enExample)
CN (1) CN113853205A (enExample)
AU (1) AU2020243623A1 (enExample)
CA (1) CA3133037A1 (enExample)
IL (1) IL286477A (enExample)
WO (1) WO2020188570A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021260696A1 (en) 2020-06-22 2021-12-30 Ramot At Tel-Aviv University Ltd. Multi subunit protein modules, cells expressing same and uses thereof
WO2024154122A1 (en) 2023-01-18 2024-07-25 Gilboa Therapeutics LTD Immune cells expressing a complement receptor and uses thereof
WO2024236557A1 (en) 2023-05-12 2024-11-21 Gilboa Therapeutics LTD Compositions comprising an fc domain for the treatment of medical conditions
CN117660500B (zh) * 2023-09-28 2025-01-28 上海恩凯细胞技术有限公司 核酸构建体、载体、转基因免疫细胞及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641863A (en) * 1993-09-30 1997-06-24 University Of Pennsylvania Chimeric IgG Fc receptors
ES2678094T3 (es) * 2004-07-10 2018-08-08 Fox Chase Cancer Center Líneas de células asesinas naturales genéticamente modificadas
US10144770B2 (en) * 2013-10-17 2018-12-04 National University Of Singapore Chimeric receptors and uses thereof in immune therapy
WO2015179833A1 (en) * 2014-05-23 2015-11-26 The Trustees Of The University Of Pennsylvania Compositions and methods for treating antibody resistance
WO2016040441A1 (en) * 2014-09-09 2016-03-17 Unum Therapeutics Chimeric receptors and uses thereof in immune therapy
US10577417B2 (en) * 2014-09-17 2020-03-03 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
KR20170127015A (ko) * 2015-03-13 2017-11-20 유니버시티 오브 매릴랜드, 발티모어 만능항체 매개 바이오센서

Also Published As

Publication number Publication date
IL286477A (en) 2021-10-31
WO2020188570A1 (en) 2020-09-24
CN113853205A (zh) 2021-12-28
AU2020243623A1 (en) 2021-11-04
EP3941492A1 (en) 2022-01-26
JP2022525927A (ja) 2022-05-20
US20210401893A1 (en) 2021-12-30
EP3941492A4 (en) 2023-05-03
US20250163128A1 (en) 2025-05-22

Similar Documents

Publication Publication Date Title
US12350334B2 (en) Compositions and methods for generating a persisting population of T cells useful for the treatment of cancer
US20230181643A1 (en) Use of trans-signaling approach in chimeric antigen receptors
KR102921822B1 (ko) 다중 면역 세포 유형의 동시 증폭을 위한 방법, 관련 조성물 및 암 면역요법에서 상기의 용도
ES2875959T3 (es) Composiciones y métodos para reprogramación de receptores de linfocitos T mediante el uso de proteínas de fusión
US20250163128A1 (en) T cell expressing an fc gamma receptor and methods of use thereof
JP7289293B2 (ja) Ｔ細胞の改変
US10786547B2 (en) Compositions, articles of manufacture and methods for treating cancer
US12077569B2 (en) Multi subunit protein modules, cells expressing same and uses thereof
WO2019118508A1 (en) Genetically modified immune cells targeting ny-eso-1 and methods of use thereof
WO2020236964A1 (en) Engineered expression of cell surface and secreted sialidase by car t cells for increased efficacy in solid tumors
US20240207315A1 (en) Chimeric receptors and uses thereof
US20240325535A1 (en) Compositions and methods comprising car t cells comprising prdm1 and/or nr4a3 knockout
US20240285757A1 (en) Compositions and methods for enhancing car t cell efficacy through the engineered secretion of c. perfringens neuraminidase
WO2024154122A1 (en) Immune cells expressing a complement receptor and uses thereof

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240222

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20250228

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250903

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260430